Suppr超能文献

单次口服雷贝拉唑对夜间酸突破和夜间碱性幅度的影响。

Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.

作者信息

Luo Jin-Yan, Niu Chun-Yan, Wang Xue-Qin, Zhu You-Ling, Gong Jun

机构信息

Department of Gastroenterology, The Second Hospital of Xi'an Jiaotong University, Xi'an 710004, Shanxi Province, China.

出版信息

World J Gastroenterol. 2003 Nov;9(11):2583-6. doi: 10.3748/wjg.v9.i11.2583.

Abstract

AIM

To study the effect of rabeprazole (RAB) on nocturnal acid breakthrough (NAB) and nocturnal alkaline amplitude (NAKA) and to compare it with omeprazole (OME) and pantoprazole (PAN).

METHODS

By an open comparative study, forty patients with active peptic ulcer were randomly assigned to receive one of the three PPIs (proton pump inhibitor) with a single oral dose. They were divided into RAB group (10 mg), OME group (20 mg) and PAN group (40 mg). Twenty healthy volunteers were enrolled to the control group (without taking any drug). Intragastric pH monitoring was then performed 1 hour before and 24 hours after the dose was given.

RESULTS

No clinically undesirable signs and symptoms possibly attributed to the administration of RAB or OME and PAN were recognizable throughout the study period. All subjects completed the study according to the protocol. All data were processed by a computer using the Student t test or t' test followed by an analysis of covariance. P<0.05 was considered to have statistical significance. The intragastric pH of NAB was significantly higher in RAB group (1.84+/-0.55) than in either OME group (1.15+/-0.31) or PAN group (1.10+/-0.30) (both P<0.01). RAB produced a longer sustaining time (4.65+/-1.22 h) on NAKA than OME (3.22+/-1.89 h) (P<0.05), PAN (3.15+/-1.92 h) (P<0.05), and the sustaining time of NAKA in RAB group was longer than that in the healthy control group (P<0.01) too. In addition, RAB produced a much higher pH on NAKA (6.41+/-0.45) in comparison with PAN (6.01+/-0.92) (P<0.05).

CONCLUSION

A single oral dose of 10 mg RAB may increase the pH of NAB and shorten the sustaining time of NAB, and it may increase the pH of NAKA as well as prolong the sustaining time of NAKA.

摘要

目的

研究雷贝拉唑(RAB)对夜间酸突破(NAB)和夜间碱潮幅度(NAKA)的影响,并与奥美拉唑(OME)和泮托拉唑(PAN)进行比较。

方法

采用开放对照研究,将40例活动性消化性溃疡患者随机分为三组,分别单次口服三种质子泵抑制剂(PPI)之一。分为RAB组(10毫克)、OME组(20毫克)和PAN组(40毫克)。选取20名健康志愿者作为对照组(不服用任何药物)。给药前1小时和给药后24小时进行胃内pH监测。

结果

在整个研究期间,未发现可能归因于RAB、OME或PAN给药的临床不良体征和症状。所有受试者均按方案完成研究。所有数据通过计算机使用Student t检验或t'检验,随后进行协方差分析。P<0.05被认为具有统计学意义。RAB组NAB的胃内pH值(1.84±0.55)显著高于OME组(1.15±0.31)和PAN组(1.10±0.30)(均P<0.01)。RAB对NAKA的维持时间(4.65±1.22小时)长于OME(3.22±1.89小时)(P<0.05)、PAN(3.15±1.92小时)(P<0.05),且RAB组NAKA的维持时间也长于健康对照组(P<0.01)。此外,与PAN(6.01±0.92)相比,RAB在NAKA时产生的pH值更高(6.41±0.45)(P<0.05)。

结论

单次口服10毫克RAB可能会提高NAB的pH值并缩短NAB的维持时间,同时可能会提高NAKA的pH值并延长NAKA的维持时间。

相似文献

1
Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.
World J Gastroenterol. 2003 Nov;9(11):2583-6. doi: 10.3748/wjg.v9.i11.2583.
8
The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers.
Aliment Pharmacol Ther. 1999 Sep;13(9):1195-203. doi: 10.1046/j.1365-2036.1999.00545.x.
9
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-14. doi: 10.1046/j.1365-2036.2003.01496.x.
10
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x.

引用本文的文献

本文引用的文献

2
The pharmacology and clinical relevance of proton pump inhibitors.
Curr Gastroenterol Rep. 2002 Dec;4(6):459-62. doi: 10.1007/s11894-002-0021-3.
3
Assessment of duodenogastric reflux by combined continuous intragastric pH and bilirubin monitoring.
World J Gastroenterol. 2002 Apr;8(2):382-4. doi: 10.3748/wjg.v8.i2.382.
4
Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
Gastroenterology. 2002 Mar;122(3):625-32. doi: 10.1053/gast.2002.31876.
5
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
Aliment Pharmacol Ther. 2001 Sep;15(9):1351-6. doi: 10.1046/j.1365-2036.2001.01050.x.
6
Reflux disease: the disorder of the third millennium.
Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S5-11.
8
Improving on PPI-based therapy of GORD.
Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S35-41.
9
Shortcomings of the first-generation proton pump inhibitors.
Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S29-33.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验